Enteric-coated mycophenolate sodium (EC-MPS)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreas Transplantation
Conditions
Pancreas Transplantation, Kidney Transplantation
Trial Timeline
Nov 1, 2005 → Jan 1, 2008
NCT ID
NCT00267150About Enteric-coated mycophenolate sodium (EC-MPS)
Enteric-coated mycophenolate sodium (EC-MPS) is a phase 3 stage product being developed by Novartis for Pancreas Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00267150. Target conditions include Pancreas Transplantation, Kidney Transplantation.
What happened to similar drugs?
1 of 4 similar drugs in Pancreas Transplantation were approved
Approved (1) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00405652 | Phase 3 | Completed |
| NCT00529269 | Approved | Completed |
| NCT00369278 | Phase 3 | Completed |
| NCT00537862 | Approved | Completed |
| NCT00267150 | Phase 3 | Completed |
| NCT00149968 | Approved | Completed |
| NCT00238953 | Approved | Completed |
| NCT00239083 | Approved | Completed |
| NCT00149942 | Approved | Completed |
| NCT00150020 | Approved | Completed |
| NCT00154206 | Approved | Completed |
| NCT00154232 | Approved | Completed |
| NCT00150007 | Approved | Completed |
| NCT00284921 | Phase 3 | Terminated |
| NCT00240955 | Approved | Completed |
| NCT00312143 | Approved | Completed |
| NCT00154245 | Approved | Completed |
| NCT00239070 | Phase 3 | Completed |
| NCT00239018 | Approved | Completed |
| NCT00238940 | Phase 3 | Completed |
Competing Products
20 competing products in Pancreas Transplantation